Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Clinical trial NCT00988169 · TERMINATED
Trial details
- NCT number
- NCT00988169
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2009-09-01
- Primary completion
- 2010-05-01
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.